Valneva SE announced that Adimmune was granted marketing approval for Valneva's Japanese encephalitis (JE) vaccine by the Taiwanese Food & Drug Administration (TFDA). The product is expected to be marketed in Taiwan under the trade name JEVAL®. This approval follows the agreement signed in 2014 between Valneva and Adimmune granting Adimmune the right to commercialize JEVAL® in Taiwan, including the right to locally fill and pack JEVAL® by using bulk product delivered by Valneva.
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
3.494 EUR | +0.69% | +4.17% | -25.97% |
07:12am | Valneva: primary vaccinations completed for VALOR trial | CF |
07-17 | Pfizer Inc. and Valneva SE Announce Primary Vaccination Series Completion | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.97% | 528M | |
+24.74% | 47.54B | |
-0.47% | 41.96B | |
+46.17% | 41.55B | |
+25.40% | 30.36B | |
+17.96% | 27.61B | |
-4.47% | 28.7B | |
+50.73% | 14.7B | |
+42.56% | 13.51B | |
+1.46% | 12.34B |
- Stock Market
- Equities
- VLA Stock
- News Valneva
- Valneva SE Announces Approval of Japanese Encephalitis Vaccine Through Commercial Partner Adimmune in Taiwan